Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 30 articles: HTML format

Single Articles

April 2024
1. SCHULER M, Hense J, Darwiche K, Michels S, et al
   Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
   J Nucl Med. 2024 Apr 4:jnumed.123.266979. doi: 10.2967/jnumed.123.266979.
   PubMed     Abstract available
   
   
   March 2024
2. THOR M, Lee C, Sun L, Patel P, et al
   An (18)F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy.
   J Nucl Med. 2024 Mar 14:jnumed.123.266965. doi: 10.2967/jnumed.123.266965.
   PubMed     Abstract available
   
   
   
3. LI C, Chen Q, Tian Y, Chen J, et al
   (68)Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression.
   J Nucl Med. 2024 Mar 7:jnumed.123.266806. doi: 10.2967/jnumed.123.266806.
   PubMed     Abstract available
   
   
   
4. HOVHANNISYAN-BAGHDASARIAN N, Luporsi M, Captier N, Nioche C, et al
   Promising Candidate Prognostic Biomarkers in [(18)F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients.
   J Nucl Med. 2024 Mar 7:jnumed.123.266331. doi: 10.2967/jnumed.123.266331.
   PubMed     Abstract available
   
   
   
5. CUZZANI G, Fortunati E, Zanoni L, Nanni C, et al
   Case Report: Pulmonary Actinomyces Infection Mimics Lung Cancer on [(68)Ga]Ga-FAPI PET/CT.
   J Nucl Med. 2024 Mar 7:jnumed.123.267155. doi: 10.2967/jnumed.123.267155.
   PubMed    
   
   
   February 2024
6. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
   Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
   J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
   PubMed     Abstract available
   
   
   
7. BOURBONNE V, Morjani M, Pradier O, Hatt M, et al
   PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy.
   J Nucl Med. 2024 Feb 15:jnumed.123.266749. doi: 10.2967/jnumed.123.266749.
   PubMed     Abstract available
   
   
   
8. LIU Z, Mhlanga JC, Xia H, Siegel BA, et al
   Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data.
   J Nucl Med. 2024 Feb 15:jnumed.123.266018. doi: 10.2967/jnumed.123.266018.
   PubMed     Abstract available
   
   
   November 2023
9. QUAN Z, Han Z, Yang Y, Wang J, et al
   Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes.
   J Nucl Med. 2023 Nov 16:jnumed.123.266002. doi: 10.2967/jnumed.123.266002.
   PubMed     Abstract available
   
   
   October 2023
10. LI X, Ye J, Wang J, Quan Z, et al
    First-in-Humans PET Imaging of KRAS(G12C) Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [(18)F]PFPMD.
    J Nucl Med. 2023 Oct 12:jnumed.123.265715. doi: 10.2967/jnumed.123.265715.
    PubMed     Abstract available
    
    
    July 2023
11. KERSTING D, Sandach P, Sraieb M, Wiesweg M, et al
    (68)Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.
    J Nucl Med. 2023 Jul 20:jnumed.123.265664. doi: 10.2967/jnumed.123.265664.
    PubMed     Abstract available
    
    
    June 2023
12. WATABE T, Naka S, Tatsumi M, Kamiya T, et al
    Initial Evaluation of [(18)F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions.
    J Nucl Med. 2023 Jun 2:jnumed.123.265486. doi: 10.2967/jnumed.123.265486.
    PubMed     Abstract available
    
    
    April 2023
13. COLOVIC M, Yang H, Southcott L, Merkens H, et al
    Comparative Evaluation of [(18)F]5-Fluoroaminosuberic Acid and (4S)-4-3-[(18)F]fluoropropyl)-l-Glutamate as System xC--Targeting Radiopharmaceuticals.
    J Nucl Med. 2023 Apr 28:jnumed.122.265254. doi: 10.2967/jnumed.122.265254.
    PubMed     Abstract available
    
    
    December 2022
14. SHIYAM SUNDAR LK, Hacker M, Beyer T
    Whole-body PET imaging: A catalyst for whole-person research?
    J Nucl Med. 2022 Dec 2:jnumed.122.264555. doi: 10.2967/jnumed.122.264555.
    PubMed     Abstract available
    
    
    August 2022
15. BOULEAU A, Nozach H, Dubois S, Kereselidze D, et al
    Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of (89)Zr-Labeled Anti-PD-L1 Antibody Formats.
    J Nucl Med. 2022;63:1259-1265.
    PubMed     Abstract available
    
    
    June 2022
16. STERBIS E, Liang R, Trivedi P, Kwak J, et al
    Lack of adherence to guideline-based imaging prior to subsequent radiation in patients with non-small cell lung cancer: Impact on patient outcomes.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264131. doi: 10.2967/jnumed.122.264131.
    PubMed     Abstract available
    
    
    April 2022
17. KUNIHIRO AG, Sarrett SM, Lastwika KJ, Solan JL, et al
    CD133 as a Biomarker for an Autoantibody-to-ImmunoPET Paradigm for the Early Detection of Small Cell Lung Cancer.
    J Nucl Med. 2022 Apr 28. pii: jnumed.121.263511. doi: 10.2967/jnumed.121.263511.
    PubMed     Abstract available
    
    
    March 2022
18. BUCK AK, Haug A, Dreher N, Lambertini A, et al
    Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using (68)Ga-PentixaFor PET.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263693. doi: 10.2967/jnumed.121.263693.
    PubMed     Abstract available
    
    
    
19. YUSUFALY TI, Mell LK
    Reply: Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful.
    J Nucl Med. 2022;63:495.
    PubMed    
    
    
    
20. ZHANG L, Zhang B
    Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful.
    J Nucl Med. 2022;63:494-495.
    PubMed    
    
    
    February 2022
21. ZIDAN L, Iravani A, Oleinikov K, Ben-Haim S, et al
    Efficacy and Safety of (177)Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.
    J Nucl Med. 2022;63:218-225.
    PubMed     Abstract available
    
    
    December 2021
22. KOLINGER GD, Vallez Garcia D, Kramer GM, Frings V, et al
    Effects of tracer uptake time in non-small cell lung cancer (18)F-FDG PET radiomics.
    J Nucl Med. 2021 Dec 21. pii: jnumed.121.262660. doi: 10.2967/jnumed.121.262660.
    PubMed     Abstract available
    
    
    August 2021
23. FARWELL MD, Gamache RF, Babazada H, Hellmann MD, et al
    CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of (89)Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262485. doi: 10.2967/jnumed.121.262485.
    PubMed     Abstract available
    
    
    
24. SMIT J, Borm FJ, Niemeijer AN, Huisman MC, et al
    PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262473. doi: 10.2967/jnumed.121.262473.
    PubMed     Abstract available
    
    
    July 2021
25. ZHOU X, Jiang J, Yang X, Liu T, et al
    First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
    PubMed     Abstract available
    
    
    
26. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
    Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
    PubMed     Abstract available
    
    
    
27. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
    First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
    PubMed     Abstract available
    
    
    May 2021
28. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed     Abstract available
    
    
    January 2021
29. LAFFON E, Marthan R
    Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
    J Nucl Med. 2021;62:144.
    PubMed    
    
    
    June 2020
30. FERDINANDUS J, Barbato F, Chodyla M, Fendler WP, et al
    Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
    J Nucl Med. 2020 Jun 12. pii: jnumed.120.245803. doi: 10.2967/jnumed.120.245803.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.